DaVita (DVA)
(Delayed Data from NYSE)
$150.30 USD
+0.34 (0.23%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $150.29 -0.01 (-0.01%) 7:58 PM ET
1-Strong Buy of 5 1
A Value B Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$150.30 USD
+0.34 (0.23%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $150.29 -0.01 (-0.01%) 7:58 PM ET
1-Strong Buy of 5 1
A Value B Growth C Momentum A VGM
Zacks News
Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.
HealthEquity (HQY) Q3 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust performances in the majority of its segments, in the third quarter of fiscal 2024.
Accuray (ARAY) Launches VitalHold in Japan for Use With Radixact
by Zacks Equity Research
Accuray's (ARAY) VitalHold is likely to transform breast cancer treatment in Japan by integrating SGRT for precise radiotherapy. It may become a game-changer for patients and medical staff.
BD (BDX) Launches Advanced Vascular Access Management System
by Zacks Equity Research
BD's (BDX) SiteRite 9 Ultrasound System is likely to revolutionize vascular care by enhancing clinician efficiency and setting a new standard in first-attempt success.
West Pharmaceutical's (WST) New Launch to Expand Portfolio
by Zacks Equity Research
West Pharmaceutical's (WST) latest addition to its portfolio is likely to address the critical need for more drug preparation and delivery options at the point of care.
Best Growth Stocks to Buy for December 5th
by Zacks Equity Research
LMB, DVA and PK made it to the Zacks Rank #1 (Strong Buy) growth stocks list on December 5, 2023.
The Zacks Analyst Blog Highlights Cboe Global Markets, Gartner, Intel, Royal Caribbean Cruises and DaVita
by Zacks Equity Research
Cboe Global Markets, Gartner, Intel, Royal Caribbean Cruises and DaVita are included in this Analyst Blog.
Here's Why You Should Invest in Haemonetics (HAE) Right Now
by Zacks Equity Research
Investors are optimistic about Haemonetics (HAE) on consistent growth performance and raised guidance.
McKesson (MCK) Announces Availability of FDA-Cleared Drug
by Zacks Equity Research
The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for breast cancer.
Top 5 High-Flying S&P 500 Stocks of November With More Upside
by Nalak Das
Five S&P 500 stocks with more potential are: IT, INTC, RCL, CBOE, DVA.
Reasons to Retain Stryker (SYK) Stock in Your Portfolio Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio.
Nevro's (NVRO) Latest Buyout to Boost SI Joint Pain Treatment
by Zacks Equity Research
Nevro's (NVRO) latest acquisition is likely to bring long-term pain relief to people suffering from chronic low back pain associated with the SI joint.
Philips (PHG) Adds Smart Fit Coils to Boost Diagnostic Imaging
by Zacks Equity Research
Philips (PHG) launches three MR Smart Fit coils, namely TorsoCardiac 1.5T, 1.5T shoulder and Knee 3.0T, enhancing flexibility, reducing patient setup time and improving image quality resolution.
Revvity (RVTY) Launches New Molecular Testing for Newborns
by Zacks Equity Research
Revvity's (RVTY) EONIS Q System is set to transform SMA and SCID testing, advancing global healthcare for infants.
Reasons to Add Intuitive Surgical (ISRG) to Your Portfolio Now
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to raise optimism among investors, owing to its strength in robotics.
3 Reasons to Retain Inspire Medical (INSP) Stock for Now
by Zacks Equity Research
Inspire Medical's (INSP) focus on R&D raises optimism about the stock.
Inari Medical's (NARI) PEERLESS II RCT to Boost Patient Outcome
by Zacks Equity Research
Inari Medical's (NARI) latest announcement of first patient enrollment in PEERLESS II RCT is likely to aid in changing guidelines in treating intermediate-risk PE patients globally.
Zacks.com featured highlights DaVita, Brinker International, CNA Financial and Integer Holdings
by Zacks Equity Research
DaVita, Brinker International, CNA Financial and Integer Holdings have been highlighted in this Screen of The Week article.
Reasons to Retain ShockWave Medical (SWAV) in Your Portfolio
by Zacks Equity Research
ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.
Patterson Companies (PDCO) Q2 Earnings Miss, EPS View Lowered
by Zacks Equity Research
Patterson Companies' (PDCO) second-quarter fiscal 2024 results reflect improvement in Dental Consumable sales, which were offset by lower Dental Equipment sales. Animal health sales improve.
4 Stocks Trading Near 52-Week High That Can Climb Further
by Vasundhara Sawalka
Investors target stocks that have been on a bullish run lately. Stocks like DVA, EAT, CNA and ITGR that are seeing price strength have a high chance of carrying the momentum forward.
Reasons to Retain West Pharmaceutical (WST) in Your Portfolio
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.
Reasons to Retain The Cooper Companies (COO) in Your Portfolio
by Zacks Equity Research
The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is concerning.
Philips (PHG) Bolsters Diagnostic Imaging With New Launches
by Zacks Equity Research
Philips (PHG) unveils an array of AI-enabled innovations at RSNA23 to enhance diagnostic imaging capabilities across healthcare providers.
5 Finest PEG-Based Value Stocks to Buy Now
by Urmimala Biswas
Here are five stocks that match our screening criteria ¿¿¿ FOXA, DVA, LDOS, BLD and ITRI.
Here's Why Investors Should Retain Abbott (ABT) Stock Now
by Zacks Equity Research
Investors are optimistic about Abbott (ABT) driven by expansion in the global market and raised guidance.